



CERTIFICATE OF ANALYSIS

COA Number: RUO-26-71F09B8F | ORIGINAL - VERSION 1

SAMPLE SUMMARY

ISSUED TO	DECLARED IDENTITY	ISSUE DATE	
Prosper Labs	Ipamorelin	Aug 11, 2026	
RUO SAMPLE ID	DECLARED LOT NUMBER	DECLARED CONTENT	DECLARED FORM
RUO-2026-CDD41A8E-18	IP-10-080326	10 mg / vial	Lyophilized powder


ANALYTICAL COMPOSITION AND IDENTITY

PURITY RESULT		VIAL 1	VIAL 2	AVERAGE	STATUS
PERCENTAGE PURITY		99.91%	99.94%	99.92%	PASS
COMPONENT	TARGET	VIAL 1	VIAL 2	AVERAGE	IDENTITY / STATUS
Ipamorelin	10.00 mg	10.89 mg	10.94 mg	10.91 mg	CONFIRMED / PASS

COMPREHENSIVE 10-TEST ANALYTICAL PANEL

ANALYSIS	METHOD	REPORTED RESULT	ASSESSMENT
Molecular Identity Confirmation	LC-MS/HRMS	Identity confirmed	PASS
Chromatographic Purity	RP-HPLC-UV/DAD	99.91% / 99.94% (average 99.93%)	PASS
Net Peptide Content	Quantitative assay	10.89 / 10.94 mg (average 10.92 mg)	PASS
Vial-to-Vial Conformity Assessment	Multi-vial quantitative study	2/2 vials within criteria	PASS
Microbial Analysis (PCR)	Validated PCR-based microbial assay	No Detectable Microbial DNA	PASS
Bacterial Endotoxin	LAL - USP <85>	<=0.05 EU/mL	PASS
Heavy Metals	ICP-MS	Below reporting limit	PASS
Residual solvents	Headspace GC	Not detected	PASS
Reconstitution and Clarity	Visual assessment after reconstitution	Clear, colorless; no visible particles	PASS
Fentanyl Screen	Validated targeted LC-MS/MS	Not detected	PASS

RP-HPLC-UV CHROMATOGRAPHIC EVIDENCE



CONTROLLED REPORT STATUS

Evidence-backed panel recorded by RUO Eagle

VERIFY REPORT

Scan to confirm status and issued PDF



Results apply only to the submitted specimens and analyses shown, including the two identified vials; they do not establish lot-wide uniformity. Research use only. Verification authenticates RUO Eagle issuance; it does not establish clinical suitability.